Aleksandra Kowalczyk

Aleksandra Kowalczyk started their work experience as a Research Fellow at Jagiellonian University in 2007. Aleksandra then became a Post-doctoral fellow at University Health Network in 2008, where they focused on the interaction between iTregs and DCs, as well as isolating and characterizing TILs from lung cancer patients. In 2012, Kowalczyk joined CureVac AG as a Scientist, where they studied the mechanism of action of mRNA-based vaccines and developed strategies to enhance immune responses. Aleksandra later became a Senior Scientist at CureVac AG before moving on to Boehringer Ingelheim in 2016, where they currently hold the position of Head of Laboratory/Principal Scientist. At Boehringer Ingelheim, Kowalczyk and their team are focused on developing new treatment modalities against cancer through collaborations and seeking scientific and in-licensing opportunities.

Aleksandra Kowalczyk's education history includes a Doctor of Philosophy with Honors in Biochemistry/Immunology from Jagiellonian University, which they obtained from 2002 to 2007. Prior to that, they completed their Master of Science with Honors in Biotechnology/Molecular Biology at Jagiellonian University from 1997 to 2002. Aleksandra'searlier education includes studies in Biology/Chemistry/Bilingual with German as a second language at II LO Krakow from 1992 to 1997. In addition to their formal education, Aleksandra Kowalczyk has obtained various certifications, including in Private Equity and Venture Capital from Università Bocconi, Building Your Leadership Skills from HEC Paris, Startup Valuation Methods from Duke University, Innovation for Impact (i4i) The Carlson-Polizzotto Method of Value Creation from D'Amore-McKim School of Business at Northeastern University, Business English: Networking from the University of Washington, and Design and Interpretation of Clinical Trials from The Johns Hopkins University.